Coreline Soft Launches Revolutionary AVIEW AI Solution at ECR 2025 for Enhanced Lung Cancer Screening
Coreline Soft, a leader in medical AI, is set to showcase its cutting-edge AVIEW solution at the European Congress of Radiology (ECR) 2025. This major event, taking place from February 26 to March 2 at the Austria Center Vienna, attracts radiologists and medical device companies from all over the globe. Coreline's presentation will include their flagship product, AVIEW (LCS Plus), at booth #107, with a focus on how AI can transform the landscape of lung cancer screening.
The urgency for improved lung cancer screening tools is increasing across Europe, where many countries are either rolling out or enhancing their screening projects. Coreline Soft is leveraging its experience and success in these initiatives, as well as their deep understanding of cloud-based AI image management, to introduce a more effective AVIEW solution. This new version integrates lessons learned and research findings, placing Coreline Soft at the forefront of AI-driven diagnostic advancements in Europe.
The enhanced AVIEW system promises not only efficient processing but also robust security and stability for managing large datasets involved in lung cancer screenings. One of its key innovations is the revamped user interface (UI) and user experience (UX), allowing healthcare professionals to access pertinent information swiftly and seamlessly.
Coreline Soft emphasizes the critical nature of collaboration in the medical field, especially in light of recent trends where AI technologies are becoming essential. According to Jason (Junghyuck) Suh, the Overseas Business Director at Coreline Soft, the implementation of their AI solutions in successful projects such as the EU-led Lung Cancer Screening Project (4ITLR) showcases the value of their technology. Moreover, recent endorsements from German health authorities deeming AI as a primary diagnostic tool highlight the escalating acceptance of such technologies across Europe, including recommendations surfacing in France.
The European Journal of Cancer has already published findings indicating the potential effectiveness of the AVIEW LCS as a primary tool for lung screenings. Coreline Soft is quickly positioning itself to meet the continental demand for AI diagnostic solutions, demonstrating its commitment to enhancing accuracy, speed, and collaboration in lung cancer screenings. With the recent acquisition of certifications including GDPR compliance, Coreline aims to solidify its foothold in the global market with its superior AI-powered screening tools.
The ECR 2025 event offers a platform for Coreline Soft not just to unveil the AVIEW lineup, but to shape the future of lung cancer diagnostics in Europe and beyond. Their dedicated approach to research, development, and collaboration is setting a new standard in medical imaging, and the upcoming conference is expected to highlight these advancements, showcasing how AI can effectively revolutionize traditional medical practices.
The urgency for improved lung cancer screening tools is increasing across Europe, where many countries are either rolling out or enhancing their screening projects. Coreline Soft is leveraging its experience and success in these initiatives, as well as their deep understanding of cloud-based AI image management, to introduce a more effective AVIEW solution. This new version integrates lessons learned and research findings, placing Coreline Soft at the forefront of AI-driven diagnostic advancements in Europe.
The enhanced AVIEW system promises not only efficient processing but also robust security and stability for managing large datasets involved in lung cancer screenings. One of its key innovations is the revamped user interface (UI) and user experience (UX), allowing healthcare professionals to access pertinent information swiftly and seamlessly.
Coreline Soft emphasizes the critical nature of collaboration in the medical field, especially in light of recent trends where AI technologies are becoming essential. According to Jason (Junghyuck) Suh, the Overseas Business Director at Coreline Soft, the implementation of their AI solutions in successful projects such as the EU-led Lung Cancer Screening Project (4ITLR) showcases the value of their technology. Moreover, recent endorsements from German health authorities deeming AI as a primary diagnostic tool highlight the escalating acceptance of such technologies across Europe, including recommendations surfacing in France.
The European Journal of Cancer has already published findings indicating the potential effectiveness of the AVIEW LCS as a primary tool for lung screenings. Coreline Soft is quickly positioning itself to meet the continental demand for AI diagnostic solutions, demonstrating its commitment to enhancing accuracy, speed, and collaboration in lung cancer screenings. With the recent acquisition of certifications including GDPR compliance, Coreline aims to solidify its foothold in the global market with its superior AI-powered screening tools.
The ECR 2025 event offers a platform for Coreline Soft not just to unveil the AVIEW lineup, but to shape the future of lung cancer diagnostics in Europe and beyond. Their dedicated approach to research, development, and collaboration is setting a new standard in medical imaging, and the upcoming conference is expected to highlight these advancements, showcasing how AI can effectively revolutionize traditional medical practices.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.